|
1.
|
|
8 p, 252.0 KB |
Is There A Role for Limited Parotid Resections for Primary Malignant Parotid Tumors?
/
Quer, Miquel (Universitat Autonòma de Barcelona. Departamento de Cirugía) ;
Olsen, Kerry D. (Mayo Clinic. Department of Otorhinolaryngology) ;
Silver, Carl E. (University of Arizona College of Medicine. Department of Surgery) ;
Hamoir, Marc (St Luc University Hospital and King Albert II Cancer Institute. Department of Head and Neck Surgery) ;
Mäkitie, Antti A. (University of Helsinki. Faculty of Medicine) ;
Rodrigo, Juan P. (Hospital Universitario Central de Asturias. Department of Otolaryngology) ;
Vander Poorten, Vincent (University Hospitals Leuven. Otorhinolaryngology-Head and Neck Surgery and Department of Oncology) ;
Takes, Robert P. (Radboud University Medical Center. Department of Otolaryngology-Head and Neck Surgery) ;
Hellquist, Henrik (University of Algarve. Department of Biomedical Sciences and Medicine) ;
García Lorenzo, Jacinto (Universitat Autonòma de Barcelona. Departament de Cirurgia) ;
Guntinas-Lichius, Orlando Jena University Hospital.Department of Otorhinolaryngology ;
de Bree, Remco (University Medical Center Utrecht. Department of Head and Neck Surgical Oncology) ;
Suárez, Carlos (Instituto de Investigación Sanitaria del Principado de Asturias) ;
Kowalski, Luiz P. (Centro de Tratamento e Pesquisa Hospital do Cancer A.C. Camargo. Department Otorhinolaryngology-Head and Neck Surgery) ;
Vartanian, José G. (Centro de Tratamento e Pesquisa Hospital do Cancer A.C. Camargo. Department Otorhinolaryngology-Head and Neck Surgery) ;
Sanabria, Alvaro (Universidad de Antioquia. Department of Surgery, School of Medicine) ;
Shaha, Ashok R. (Memorial Sloan Kettering Cancer Center) ;
Zbären, Peter (Universitätsspital Bern. Department of Otorhinolaryngology-Head and Neck Surgery) ;
Rinaldo, Alessandra (University of Udine. School of Medicine) ;
Ferlito, Alfio (International Head and Neck Scientific Group)
Background: Lateral or total parotidectomy are the standard surgical treatmentsfor malignant parotid tumors. However, some authors have proposed a more limited procedure. (2) Methods: We performed a review of the literature on this topic. [...]
2020 -  10.3390/surgeries1010002
Surgeries, Vol. 1 Núm. 1 (2020) , p. 2
|
|
|
2.
|
|
|
3.
|
|
13 p, 501.3 KB |
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function
/
Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Rodón, Jordi (Hospital Universitari Vall d'Hebron) ;
Machiels, Jean-Pascal (Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium) ;
Rottey, Sylvie (Department of Medical Oncology, University Hospital of Ghent and Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium) ;
Damian, Silvia (Department of Medical Oncology, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy) ;
Baird, Richard (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ;
Garcia-Corbacho, Javier (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ;
Mathijssen, Ron H. J. (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands) ;
Clot, Pierre-François (Sanofi, Chilly-Mazarin, France) ;
Wack, Claudine (Sanofi, Chilly-Mazarin, France) ;
Shen, Liji (Sanofi, Bridgewater, NJ USA) ;
de Jonge, Maja J. A. (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands)
Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. [...]
2016 - 10.1007/s00280-016-3175-7
Cancer Chemotherapy and Pharmacology, Vol. 78 (october 2016) , p. 1185-1197
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
13 p, 3.5 MB |
Diets high in corn oil or extra-virgin olive oil differentially modify the gene expression profile of the mammary gland and influence experimental breast cancer susceptibility
/
Moral Cabrera, Raquel (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Escrich Navarro, Raquel (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Solanas i Garcia, Montserrat (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Vela Sarrión, Elena (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ruiz de Villa, M. Carme (Universitat de Barcelona) ;
Escrich Escriche, Eduard (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Nutritional factors, especially dietary lipids, may have a role in the etiology of breast cancer. We aimed to analyze the effects of high-fat diets on the susceptibility of the mammary gland to experimental malignant transformation. [...]
2015 - 10.1007/s00394-015-0958-2
European Journal of Nutrition, Vol. 55 (June 2015) , p. 1397-1409
|
|
|
7.
|
|
9 p, 403.1 KB |
Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors : a population-based study
/
Rubió Casadevall, Jordi (Institut Català d'Oncologia de Girona) ;
Borràs, Joan Lluis (Hospital Universitari Sant Joan. Departament d'Oncologia Mèdica) ;
Carmona-García, Maria Carme (Institut d'Investigació Biomèdica de Girona) ;
Ameijide, Alberto (Fundació per a la Investigació i Prevenció del Càncer. Universitat Rovira i Virgili) ;
Gonzalez-Vidal, Allan (Institut d'Investigació Biomèdica Sant Pau) ;
Ortiz, Maria Rosa (Hospital Universitari Josep Trueta) ;
Bosch, Ramon (Hospital Universitari Verge de la Cinta) ;
Riu, Francesc (Hospital Universitari Sant Joan. Departament de Patologia) ;
Parada, David (Hospital Universitari Sant Joan. Departament de Patologia) ;
Martí, Esther (Hospital Santa Tecla Departament de Patologia) ;
Miró, Josefina (Clinica Girona Departament de Patologia) ;
Sirvent, Juan Jose (Hospital Universitary Joan XXIII. Departament de Patologia) ;
Galceran, Jaume (Red Temática de Investigación Cooperativa en Cáncer (RTICC), Girona, Spain) ;
Marcos-Gragera, Rafael (Institut d'Investigació Biomèdica de Girona) ;
Universitat Autònoma de Barcelona
Gastrointestinal stromal tumors are sarcomas of the digestive tract characterized by mutations mainly located in the c-KIT or in the platelet-derived growth factor receptor (PDGFR)-alpha genes. Mutations in the BRAF gene have also been described. [...]
2015 - 10.1186/s12957-015-0474-0
World Journal of Surgical Oncology, Vol. 13 (february 2015)
|
|
|
8.
|
|
29 p, 14.8 MB |
Metabolomics of Therapy Response in Preclinical Glioblastoma : a Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment
/
Arias-Ramos, Nuria (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ;
Ferrer-Font, Laura (Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Lope Piedrafita, Silvia (Universitat Autònoma de Barcelona. Servei de Ressonància Magnètica Nuclear) ;
Mocioiu, Victor (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Julià Sapé, Ma. Margarita (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Pumarola i Batlle, Martí (Universitat Autònoma de Barcelona. Departament de Medicina i Cirurgia Animals) ;
Arús i Caraltó, Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ;
Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular)
Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a short survival time even after aggressive therapy. Non-invasive surrogate biomarkers of therapy response may be relevant for improving patient survival. [...]
2017 - 10.3390/metabo7020020
Metabolites, Vol. 7, Num. 2 (2017) , p. p1-29
|
|
|
9.
|
|
12 p, 450.2 KB |
Safety and Efficacy of 5-Aminolevulinic Acid for High Grade Glioma in Usual Clinical Practice: A Prospective Cohort Study
/
Teixidor, Pilar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Arráez, Miguel Ángel (Hospital Regional Universitario de Málaga) ;
Villalba, Glòria (Hospital del Mar (Barcelona, Catalunya)) ;
Garcia, Roser (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tardáguila, Manel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
González Sánchez, Juan José (Hospital Clínic i Provincial de Barcelona) ;
Rimbau, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vidal Guitart, Xavier (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Montané, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Background: During the last decade, the use of 5-aminolevulinic acid (5-ALA) has been steadily increasing in neurosurgery. The study's main objectives were to prospectively evaluate the effectiveness and safety of 5-ALA when used in clinical practice setting on high-grade gliomas' patients. [...]
2016 - 10.1371/journal.pone.0149244
PloS one, Vol. 11 Núm. 2 (February 2016)
|
|
|
10.
|
|
16 p, 911.4 KB |
Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients
/
Molina, David (Universidad de Castilla-La Mancha (Ciudad Real)) ;
Pérez Beteta, Julián (Universidad de Castilla-La Mancha (Ciudad Real)) ;
Martínez González, Alicia (Universidad de Castilla-La Mancha (Ciudad Real)) ;
Sepúlveda, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Peralta, Sergi (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Gil Gil, Miguel J. (Institut Català d'Oncologia) ;
Reynes, Gaspar (Hospital Universitario La Fe (València)) ;
Herrero, Ana (Hospital Universitario Miguel Servet (Zaragoza)) ;
De Las Peñas, Ramón (Consorci Hospitalari Provincial de Castelló) ;
Luque, Raquel (Hospital Universitario Virgen de las Nieves (Granada)) ;
Capellades, Jaume (Hospital del Mar (Barcelona)) ;
Balañá, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Pérez García, Víctor M. (Universidad de Castilla-La Mancha (Ciudad Real))
Background: Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. [...]
2016 - 10.1371/journal.pone.0161484
PloS one, Vol. 11 Núm. 8 (August 2016)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
